Podcasts about md anderson cancer center

In this "Giants in Plastic Surgery" episode of the PRS Global Open Deep Cuts Podcast, we speak with Professor Sydney Ch'ng, Professor of Surgery at the University of Sydney and one of the few surgeons fully trained in both head and neck surgery and plastic and reconstructive surgery. Dr Ch'ng reflects on her journey from arriving in Australia as a Malaysian Chinese woman to building a distinguished surgical career across Australia, New Zealand, Asia, and the United States. She shares what it felt like adapting to a new country, how her perspective on fitting in and standing out evolved, and the mentors who shaped her path. We discuss her route through medical school, surgical training, research, fellowships, and her transition into consultant practice, including her experience at Chang Gung Memorial Hospital in Taiwan and MD Anderson Cancer Center in Houston. Dr Ch'ng also offers insight into the challenges and rewards of combining cancer resection, reconstruction, and aesthetic surgery, and reflects on whether aesthetic training should play a larger role in plastic surgery programs. Beyond surgery, she speaks candidly about mentorship, academic publishing, setting up a practice, life outside medicine, and what it means to build a career with both technical excellence and cultural identity at its center. Your host, Dr. Vimal Gokani, is a senior Specialty Registrar in plastic surgery in London, England. Your producer & editor, Charlene Kok, is a Year 4 Medical Student in Imperial College London, England, with a keen interest in Plastic Surgery. #PRSGlobalOpen #DeepCutsPodcast #PlasticSurgery #GiantsPlasticSurgery

Toxicities related to antibody-drug conjugates (ADCs) can significantly impact quality of life for patients with locally advanced or metastatic bladder cancer, but data-driven programs can help multidisciplinary teams manage some of the most challenging adverse events. In this episode, CANCER BUZZ speaks with Cindy Y. Jiang, MD, assistant professor at MD Anderson Cancer Center, about how her institution conducted and implemented research to aid management of rashes and peripheral neuropathy associated with the ADC enfortumab vedotin combined with pembrolizumab. Guest:  Cindy Y. Jiang, MD Assistant Professor Department of GU Medical Oncology MD Anderson Cancer Center Houston, TX "It's important to assemble this team before you start on any sort of journey, because as oncologists, we're definitely not experts in skin rashes or neurological issues, and so you really need to rely heavily on those collaborators." — Cindy Y. Jiang, MD Resources: Bladder Cancer Antibody-Drug Conjugates

What if “energy healing” could be tested—and measured—in a world-class cancer research setting?In this episode of Unpacking Possibility, host Traci Stein unpacks a groundbreaking MD Anderson Cancer Center preclinical study investigating biofield therapy (energy healing) and its reported effects on pancreatic cancer in lab and animal models—including slower growth and spread.Traci shares the findings of this study and discusses them in the broader context of research on biofield therapies (including Reiki, Healing Touch, and Therapeutic Touch). She also shares a personal story about doing Reiki in an operating room for a patient who was undergoing heart surgery and how what she witnessed deepened her perspective on subtle energy. You'll also learn a simple, at-home exercise you can try to begin sensing your own energy field (as well as a friend's).In this episode you'll learn more about:- What the MD Anderson studies found- Why pancreatic cancer research needs new possibilities - Early research showing energy healing could make seeds germinate faster, surgical wounds heal better, and more- A brief look at the Bengston Healing Method and “image cycling” - A simple exercise you can try tonight to explore energy-field sensing Note: This episode is educational and not medical advice. Always consult your healthcare team about diagnosis and treatment.To learn more about Traci's self-paced, online course, “Developing Everyday Intuition,” visit: https://www.drtracistein.com/developing-everyday-intuition-courseTo receive $5 off the price of Traci's course, “Developing Everyday Intuition,” apply code ENERGY5OFF before checkout.“The Everything Guide to Integrative Pain Management,” by Traci Stein, PhD, MPH: https://a.co/d/0fji41kQTo read the MD Anderson paper: https://onlinelibrary.wiley.com/doi/10.1002/cam4.71726

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of chronic myeloid leukemia (CML) through two challenging case studies. Joined by CML experts Dr. Fadi Haddad from MD Anderson Cancer Center and Dr. Gaby Hobbs from Massachusetts General Hospital,  Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ we talked about: The initial workup for diagnosing CML, including the importance of CBC, bone marrow biopsy, and BCR-ABL testing. How to select the most optimal frontline treatment option amongst many available, considering factors like age, comorbidities, and the goal of treatment-free remission (TFR). The role of first-generation TKI, but also how newer TKIs assist in achieving deeper molecular remissions. Strategies for managing treatment breaks and monitoring patients in remission. The role of ponatinib as a pan-BCR:ABL1 inhibitor effective against all known resistance mutations, including T315I, and the optimized response-based dosing strategy to balance efficacy with safety. Tune in for valuable insights on treatment strategies, patient management, and the latest advancements in CML care. Don't forget to like, subscribe, and share your challenging case scenarios for future discussions! #ChronicMyeloidLeukemia, #CML, #TreatmentFreeRemission, #OncologyBrothers

Dr. Mei Rui is a Yale-trained molecular biophysicist, concert pianist, and clinical researcher at MD Anderson Cancer Center, where she runs trials on the measurable effects of music on the human body. In this conversation, we explore what actually happens in the brain the moment music enters it, why the auditory system is the first sense to develop in the womb and the last to go when we die, and how something as accessible as a curated playlist can outperform FDA-approved pharmaceuticals in reducing cortisol.What We Dive Into:1. Music is not a supplement to healing. In the right context, it is the intervention.2. The brain responds differently when you actually show up for the music.3. A longitudinal study in twins showed that three to four years of musical training reduced the risk of Alzheimer's and cognitive decline by 64%, an effect size found in no other single activity.THANK YOU TO OUR SPONSORS:Oneskin — Code KNOWTHYSELF for 15% off - Limited time only!https://oneskin.co/KNOWTHYSELFBASED Body Works — Code KNOWTHYSELF for 20% and a free toiletry bag!https://www.basedbodyworks.com___________00:00 Introduction: Dr. Mei Rui01:44 A Life Between Music and Science05:26 What Happens When Music Enters the Brain07:26 How the Brain Processes Sound and Music11:32 Why Minor Keys Feel Sad: The Science of Tonality14:37 Live Piano Demo: Matching Music to Mood19:06 Music in the Operating Room27:41 Music as Medicine: Clinical Applications29:10 The 32% Cortisol Study31:19 The 16 Compositional Elements of Healing Music35:11 Oxytocin, Familiarity, and the Parasympathetic Response36:18 Timbre and the Cello's Resemblance to a Mother's Voice42:31 Cymatics: Sound Made Visible45:16 The Ancient Roots of Music as Healing47:09 Listening vs. Playing an Instrument55:33 The Musician's Brain: Structural Differences57:46 Music Training and Protection Against Alzheimer's59:44 Music, Empathy, and Neural Synchrony1:01:36 The EEG Experiment: Reading André's Brain Live1:18:21 What the EEG Data Revealed1:22:26 Music, Flow State, and the Disappearance of Self1:26:55 Music as Spiritual Medicine1:30:23 How to Listen More Intentionally___________MORE FROM MEI✨Instagram: https://www.instagram.com/@meiruipianoMORE FROM KNOW THYSELF

Michael Prokopis is the CEO of DARVIS, an AI-powered company transforming healthcare inventory management through real-time visibility and autonomous solutions. Under his leadership, DARVIS is helping health systems use AI and computer vision to improve inventory accuracy, reduce waste, and prevent stockouts. Prior to DARVIS, he held senior roles at institutions including MD Anderson Cancer Center and Steward Health Care. A former US Navy Surface Warfare Officer, Michael has managed $3.2B+ in spending and driven $360M+ in savings through operational transformation and efficiency programs. In this episode… Healthcare supply chains operate under constant pressure, where missing inventory can delay care, increase costs, and create major operational headaches. Yet many hospitals still rely on outdated manual tracking systems that lack real-time visibility. How can AI help healthcare systems reduce waste, prevent shortages, and make smarter inventory decisions? For Michael Prokopis, a healthcare supply chain and operations veteran, the answer lies in combining AI-powered computer vision with real-time inventory intelligence. He highlights how DARVIS uses camera-based AI systems to track thousands of medical products across large hospital systems, reduce manual labor, and prevent costly stockouts. This technology helps healthcare teams automate replenishment, improve forecasting, and respond faster during supply disruptions. He also explains how the system continuously learns and adapts to different healthcare environments, making implementation faster and more scalable. By improving visibility and accuracy, hospitals can operate more efficiently while giving supply chain leaders stronger data for decision-making. In this episode of the Inspired Insider Podcast, host Dr. Jeremy Weisz sits down with Michael Prokopis, CEO of DARVIS, to discuss AI-driven healthcare inventory management. They explore how DARVIS uses computer vision for real-time inventory tracking, the challenges of selling technology to hospitals, and how AI reduces supply chain waste and shortages. Michael also shares lessons from his Navy and healthcare leadership experience.

In this episode, Kim Louise, Medical Intuitive & Holistic Nutritionist, speaks with John Lavack - a gifted energy healer who has worked with clients in over 46 countries for over 30 years. John blends Rapid Image Cycling (a modality developed by the late, great Dr. William Bengston) with a wide range of healing modalities including psychosomatics, neuro-linguistic programming (NLP), bioenergy balancing, intuitive development, and hands-on energy practices. Together we explore how John integrates these tools to help clients shift belief structures, release patterns, and transform health and personal life outcomes all while grounding his work in research settings including the Institute of Noetic Sciences, Beech Tree Labs, and MD Anderson Cancer Center. What you'll discover: • Amazing Stories from decades of helping to heal clients worldwide • How John combines multiple modalities for deeper healing impact • Why shifting belief frameworks matters in energy work • Practical tools like charged cotton & water for energy healing  • How science and energy healing are beginning to intersect • How you can learn Rapid Image Cycling for yourself and to heal others with it - including animals If you're curious about multi-modal energy healing, this conversation offers insight, inspiration, and practical takeaways.  Guest: John Lavack, Energy Healer and Facilitator Contact: (650) 743-4559 Host: Kim Louise, Medical Intuitive and Holistic Nutritionist To schedule a free 15-minute call with me to see if I'm the right fit for your needs, go to: www.kimlouisemedicalintuitive.com Dr. William Bengston's website regarding his research and Rapid Image Cycling classes: https://bengstonresearch.com/ Video with Dr. William Bengston on New Thinking Allowed: https://youtu.be/V-YPt6L45p0?si=RSOen83S8KqtVZhl Dr. William Bengston's video about mummifying bananas: https://youtu.be/0Ca4e3cSi3g?si=dKdV3_YyWupS1PkY Disclaimer: This content is for educational purposes only. It does not diagnose, treat, or cure. Please consult a licensed healthcare provider for medical concerns.

What happens when a cancer research institution invites energy healers into the laboratory? In this special feed takeover, Insights at the Edge presents the debut episode of Phenomena: The Science and Stories of Energy Healing—a new six-part Sounds True podcast hosted by Ivy Ross. In this episode, you'll learn about astonishing research from MD Anderson Cancer Center and the story of one patient whose surgeon saw something they had never seen before. More info at phenomenahealing.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Taking a break from their exploration of the YouCat, Eoin interviews Fr Chris Garrett. Fr Chris is a priest of the Diocese of Elphin ordained three years ago — having previously spent decades as a consultant oncologist at MD Anderson Cancer Center in Houston, Texas. Fr. Chris traces a journey from an Irish upbringing, a […] L'articolo YouChat – Fr Chris's Testimony: Mariathon Special – Fr. Chris Garrett and Eoin Brennan proviene da Radio Maria.

Host Holly Wayment brings us Houston spine surgeon Rex Marco who, after a terrible cycling accident , faced  life-changing paralysis to recovery through mindfulness, the RAIN method, and radical acceptance.   He describes what happened to him and how in one moment everything can change. His work now explores how compassion, mindfulness, and vulnerability can reshape how we live, lead, and heal. In 2019, Dr. Marco sustained a C3–4 fracture-dislocation in a cycling accident, resulting in C2 quadriplegia. Today, he serves as the Chief Medical Ambassador for the Christopher & Dana Reeve Foundation, advocating for research, cure, and improved quality of life for individuals living with spinal cord injury. He is also a certified mindfulness meditation teacher and is passionate about integrating resilience, presence, and emotional healing into medicine, leadership, and life. He's known for creative and transformative teaching and shares that his most profound transformation came through recovery, where he confronted longstanding patterns in how he related to himself and others.  This episode explores how he says acceptance, gratitude, and recovery programs transformed his leadership, clinical practice, and family life, offering actionable tools for cultivating presence and emotional safety. Dr. Rex Marco is an internationally recognized orthopedic spine and musculoskeletal oncology surgeon whose career has centered on caring for patients with complex spinal disorders and tumors. He completed his undergraduate studies at UC Irvine and conducted research at the National Institutes of Health through the Howard Hughes Medical Institute before earning his medical degree from the UCLA School of Medicine. He went on to complete surgical training at Virginia Mason Medical Center, orthopedic residency at UC Davis, and dual fellowships in musculoskeletal oncology at Memorial Sloan Kettering Cancer Center and reconstructive spine surgery at Rush University. Dr. Marco has held leadership roles at MD Anderson Cancer Center, Texas Children's Hospital, Houston Methodist Hospital, and UTHealth Houston, where he serves as Spine Fellowship Director.  

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufacturing model built around clinical proximity, the global alliance bringing TIL production to regions with no current access, and the next-generation engineered approaches redefining what these therapies can do.Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. If you missed Part 1, she explained how specific activation changes recovered a failing TIL process from 50% to 95% success in heavily pre-treated patients.Topics discussed:How close collaboration with MD Anderson accelerates clinical development and regulatory readiness (03:08)CTMC's approach to process development and adapting to innovative technologies (05:15)The value of partnership-based models versus traditional CDMO-driven approaches (06:24)Global technology transfer: building alliances to expand access to cell therapies, with a case study in Brazil (07:35)Key barriers and solutions for cell therapy manufacturing in new regions (09:41)Practical advice for scientists starting in GMP manufacturing and process development (10:46)Future directions in CAR T and TIL, including logic-gated CARs, engineered TILs, and in vivo therapies (12:24)The importance of continued innovation and collaboration to expand global patient access (17:39)Smart insight:The choice of manufacturing partner in cell therapy is not a logistics decision. It is a process development decision. CTMC's collaboration-based model exists because many early-stage developers arrive without a process robust enough to hand over. For scientists in small or mid-sized companies, engaging that kind of partnership too late, or on purely transactional terms, is one of the most avoidable risks in early clinical development.If you're interested in exploring further the concepts we touched on, such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier DetournayEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerConnect with Chantale Bernatchez:LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511CTMC website: www.ctmc.comSupport the show

In this episode of the Treating Together podcast, host Pallav Mehta, MD, medical oncologist at MD Anderson Cancer Center at Cooper University Health Care and medical director of Reimagine Care, speaks with E. Anders (Andy) Kolb, MD, president and chief executive officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society; LLS). Together, they unpack the major forces shaping change in pediatric hematologic malignancies—from biology to treatment/care delivery and advocacy—and how they converge to rapidly translate research into practice.Key Discussion PointsThe conversation explores the momentum in pediatric blood cancer research and treatment, highlighting how genomics, clinical trials, and large-scale initiatives are reshaping care. Highlights include: Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are biologically distinct from adult disease, with more structural mutations (eg, translocations) rather than targetable point mutations—limiting applicability of many adult therapies. Barriers to Progress in Pediatric Myeloid Malignancies: Despite advances, progress in pediatric myeloid malignancies lags behind due to fewer actionable targets and limited drug development incentives. Clinical Trials as the Backbone of Care: Unlike adult oncology, trial participation is deeply embedded in pediatric care, with high enrollment rates driven by limited approved therapies, strong cooperative group infrastructure, and family motivation. Measuring Impact Beyond Survival: Beyond traditional end points like overall survival, the concept of life years saved highlights the long-term impact of curing children and informs research prioritization. Survivorship as a Research Driver: Long-term treatment effects (eg, infertility, organ damage) shape modern trial design, with increasing efforts to reduce toxicity and replace chemotherapy with targeted or immune-based therapies. Global Efforts Accelerating Progress: Initiatives like Blood Cancer United's Dare to Dream are advancing research, access, and advocacy for high-risk pediatric patients.

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.Key topics discussed:Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)The ongoing search for critical cell quality attributes that correlate with patient response (27:00)In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.Smart insight: In cell therapy, manufacturing isn't just a production step. It defines the therapy itself. Because each patient's starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.If you're interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier DetournayEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerConnect with Chantale Bernatchez:LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511CTMC website: www.ctmc.comSupport the show

In this episode of Bright Spots in Healthcare, recorded live at the ViVE 2026 conference, Eric Glazer sits down with Dr. Pavitra Krishnamani from MD Anderson Cancer Center to explore what it actually takes to build scalable digital health systems. As both a practicing emergency physician and digital health innovator, Dr. Krishnamani brings a frontline perspective to one of healthcare's biggest challenges: why so many digital health tools fail to scale, and what separates technologies that succeed from those that don't. While the industry continues to invest heavily in AI, wearables, telehealth, and other digital tools, many health systems are still struggling with fragmented solutions, low adoption, and limited real-world impact. The path forward isn't more tools, it's better systems.  In this episode, you'll learn: Why workflow integration matters more than features in digital health adoption How AI, wearables, telehealth, VR, and EHRs must work together as a connected ecosystem What health systems should evaluate before bringing in new technology, including ROI, maintenance, and unintended consequences The role of human-centered design in building solutions clinicians will actually use  Why adoption fails without clinician buy-in, flexibility, and cultural alignment How to design more effective pilots and avoid common implementation pitfalls Why education and mindset are critical to scaling AI and digital health What it takes to move from siloed tools to scalable, system-level transformation Key Takeaway: "Education begets innovation" - Pavitra P. Krishnamani, MD. Scalable digital health isn't about deploying more technology, it's about aligning technology, workflows, and people into systems that actually work in practice. Learn More from Dr. Krishnamani: http://pavitramd.com/. Dr. Krishnamani expands on many of these ideas in her upcoming book: Home is Where the Health Is: How Digital Innovation and Technological Advances are Transforming Healthcare and Wellness. The book explores how technologies like AI, wearables, telehealth, and data systems are coming together to reshape healthcare delivery and move care closer to where patients live their daily lives. Connect with Dr. Krishnamani: Instagram: https://www.instagram.com/docpavitra  LinkedIn: https://www.linkedin.com/in/pavitra-krishnamani   Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business through credibility building content and trusted executive relationships, email hkrish@brightspotsventures.com About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.

This mini-series on Behind the Knife delves into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program and Cancer Surgery Standards Program. This episode highlights sentinel lymph node biopsy for breast cancer.Hosts:- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center.- Lauren Postlewait, MD, FACS, is an Associate Professor of Surgery at Emory University School of Medicine and is the Medical Director of the Breast Center at Grady Memorial Hospital in Atlanta, GA.- Chantal Reyna, MD, FACS (@kprgrl3) is a Breast surgical oncologist at Loyola University Medical Center in Chicago, IL and serves as the oncology clinical lead for the breast service line.Guest:- Susan E. Pories, MD, FACS (@SusanPoriesMD) is a professor of surgery, vice chair for quality and safety, and director of the Rutger's Breast Center at the University hospital. Learning Objectives: -       Understand the definition and identification of axillary sentinel lymph node. -       Understand the technique for injecting tracer or dye to perform sentinel lymph node biopsy. -       Understand the importance of preincision drainage evaluation and transcutaneous localization.-       Understand techniques to minimize seroma formation.Links to Papers Referenced in this EpisodeOperative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colonhttps://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/Kindle edition:https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSBSentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Lancet Oncol. 2010 Oct;11(10):927-33.https://pubmed.ncbi.nlm.nih.gov/20863759/Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection J Clin Oncol. 2016 Apr 1;34(10):1072-8.https://pubmed.ncbi.nlm.nih.gov/26811528/The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis World J Surg. 2012 Sep;36(9):2239-51. https://pubmed.ncbi.nlm.nih.gov/22569745/Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer Am J Surg. 2005 Oct;190(4):557-62.https://pubmed.ncbi.nlm.nih.gov/16164919/Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial JAMA Oncol. 2023 Nov 1;9(11):1557-1564.https://pubmed.ncbi.nlm.nih.gov/37733364/Choosing Wisely GuidelinesSociety of Surgical Oncology. Released 2016 July 12; last updated 2020 November 13. Choosing Wisely: Five Things Physicians and Patients Should Question.https://surgonc.org/wp-content/uploads/2020/11/SSO-5things-List_2020-Updates-11-2020.pdfPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewOral Board Simulator: https://app.behindtheknife.org/oral-board-simulatorTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explored: • The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings. • The importance of germline testing and next-generation sequencing (NGS) in guiding treatment decisions. • The role of neoadjuvant and adjuvant therapies, including FOLFIRINOX and Gemcitabine-based regimens. • Strategies for managing borderline resectable disease and the significance of multidisciplinary care. • The critical aspect of supportive care, including the use of pancreatic enzyme replacement therapy. • Insights into treatment options for metastatic disease, including FOLFIRINOX, NALIRIFOX, and Gemcitabine-Nab-paclitaxel. • The emerging landscape of targeted therapies for KRAS mutations and the potential of pan-RAS inhibitors. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving treatment algorithms for pancreatic cancer. Don't forget to like, subscribe, and hit the notification bell for more discussions on cancer treatment and care! #PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

The wellness industry has a problem, and Ezekiel Emanuel is one of the few people willing to call it out. In his new book, Eat Your Ice Cream: A Contrarian’s Guide to Living Longer, Healthier, and Happier, the bioethicist, oncologist, and former White House health advisor challenges both the influencers selling unproven supplements and the culture of wellness-as-self-punishment. In this episode, Emanuel makes a compelling research-backed case that the single most powerful determinant of health, longevity, and happiness is social connection, not sleep scores, protein intake, or VO2 max. Drawing on the Harvard Adult Development Study, the longitudinal study, going strong after 88 years, and other research worldwide, he explains why loneliness is biologically dangerous, and why doctors almost never ask about it. He also makes important points about retirement. When 40 hours of purposeful work becomes 40 hours of passive television, the brain pays a price. Emanuel argues that retirement requires deliberate design to replace the cognitive challenge, social contact, and structured schedule that work once provided. And he offers Ben Franklin, inventor of bifocals at 79, and still inventing at 81, as a model for what staying fully alive in later life actually looks like. Ezekiel Emanuel joins us from Washington, DC. ________________________ For More on Ezekiel Emanuel Eat Your Ice Cream: A Contrarian’s Guide to Living Longer, Healthier, and Happier Website ________________________ Bio Ezekiel J. Emanuel, MD, PhD, is the Vice Provost for Global Initiatives and the Diane v.S. Levy and Robert M. Levy University Professor. An oncologist and world leader in health policy and bioethics, he is a Special Advisor to the Director General of the World Health Organization, Senior Fellow at the Center for American Progress, and member of the Council on Foreign Relations. He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August 2011. From 2009 to 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. In this role, he was instrumental in drafting the Affordable Care Act. Dr. Emanuel is the most widely cited bioethicist in history. He has over 350 publications and has authored or edited 15 books. His recent publications include Which Country Has the World's Best Health Care (2020), Prescription for the Future (2017), Reinventing American Health Care: How the Affordable Care Act Will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System (2014) and Brothers Emanuel: A Memoir of an American Family (2013). In 2008, he published Healthcare, Guaranteed: A Simple, Secure Solution for America, which included his own recommendations for health care reform.Dr. Emanuel regularly contributes to The New York Times, The Washington Post, The Wall Street Journal, and The Atlantic and often appears on BBC, NPR, CNN, MS NOW and other media outlets. He has received numerous awards, including election to the Institute of Medicine (IOM) of the National Academy of Science and awards from the American Academy of Arts and Sciences, the Association of American Physicians, and the Royal College of Medicine (UK). He has been named a Dan David Prize Laureate in Bioethics and is a recipient of the AMA-Burroughs Wellcome Leadership Award, the Public Service Award from the American Society of Clinical Oncology, the Lifetime Achievement Award from the American Society of Bioethics and Humanities, the Robert Wood Johnson Foundation David E. Rogers Award, the President's Medal for Social Justice from Roosevelt University, and the John Mendelsohn Award from the MD Anderson Cancer Center, as well as honorary degrees from Icahn School of Medicine at Mount Sinai, Union Graduate College, the Medical College of Wisconsin, and Macalester College. Dr. Emanuel is a graduate of Amherst College. He holds a M.Sc. from Oxford University in Biochemistry and received his M.D. from Harvard Medical School and a Ph.D. in political philosophy from Harvard University. ________________________ Retirement Podcast Conversations You’ll Also Love   The Good Life – Marc Schulz, PhD Retiring: Creating a Life That Works for You – Teresa Amabile How Not to Age – Dr. Michael Greger _________________________ About The Retirement Wisdom Podcast There are many podcasts on retirement, often hosted by financial advisors with their own financial motives, that cover the money side of the street. This podcast is different. You'll get smarter about the investment decisions you'll make about the most important asset you'll have in retirement: your time. About Retirement Wisdom I help people who are retiring, but aren't quite done yet, discover what's next and build their custom version of their next life. A meaningful retirement doesn't just happen by accident. Schedule a call today to discuss how the Designing Your Life process created by Bill Burnett & Dave Evans can help you make your life in retirement a great one — on your own terms. About Your Podcast Host Joe Casey is an executive coach who helps people design their next life after their primary career and create their version of The Multipurpose Retirement.™ He created his own next chapter after a 26-year career at Merrill Lynch, where he was Senior Vice President and Head of HR for Global Markets & Investment Banking. Joe has earned Master's degrees from the University of Southern California in Gerontology (at age 60), the University of Pennsylvania, and Middlesex University (UK), a BA in Psychology from the University of Massachusetts at Amherst, and his coaching certification from Columbia University. In addition to his work with clients, Joe hosts The Retirement Wisdom Podcast, ranked in the top 1% globally in popularity by Listen Notes, with over 2 million downloads. Business Insider recognized Joe as one of 23 innovative coaches who are making a difference. He's the author of Win the Retirement Game: How to Outsmart the 9 Forces Trying to Steal Your Joy. __________________________ Wise Quotes On Wellness “Wellness should be about joie de vivre — about joy in life. It should not be only self-deprivation…Most of wellness is about don’t do stupid stuff — and most of it, we already know.” On Retirement “Most people when 40 hours of work drops out, 40 hours of TV comes in. Very passive. Not very intellectually challenging. That’s not retirement — that’s a slow decline…We don’t spend nearly enough time thinking about the brain part of retirement. Your brain is probably more important than your money.” On Willpower vs. Habits “If you have to use your willpower every time you do something, you can forget it. You have to make the wellness activity part of your habit. Doing it three to four times a week for about six weeks, that’s about what you need for a new activity to become ingrained.”  

Join Stephen Ibaraki as he sits down with Dr. Caroline Chung, Vice President, Chief Data & Analytics Officer, and Professor at MD Anderson Cancer Center, for an inspiring conversation about transforming medicine through data, technology, and human-centered innovation.In this episode, Dr. Chung shares her incredible journey—from her early years as a second-generation Canadian to leading pioneering initiatives in oncology at UBC, Princess Margaret, and MD Anderson. Discover how her personal experiences, mentorship, and fearless approach to nonlinear career paths shaped her impact in medicine and data science.Career Inflection Points: How early life experiences and family inspired a mission-driven path in medicine.Precision Medicine & Innovation: Dr. Chung's focus on brain tumors, quantitative imaging, and translational research.Leading Change: Creating multidisciplinary clinics, standardizing tumor measurement, and integrating AI in oncology.Data & Technology in Healthcare: Building enterprise-level data governance, exploring digital twins, and leveraging AI, HPC, and quantum computing.Future of Medicine: Overcoming challenges in interoperability, collaboration across sectors, and fostering the next generation of innovators.

Send a textWhat do the latest findings from the 2025 San Antonio Breast Cancer Symposium mean for people living with metastatic breast cancer? In this episode, Dr. Bora Lim of MD Anderson Cancer Center joins us to break down the most impactful research and clinical trial updates from SABCS 2025. Together we will explore advances in hormone receptor positive, HER2-positive disease and triple negative disease and discuss how these updates may influence treatment decisions right now. We also wrap up with an audience Q&A, including questions about GLP-1 medications.Listen in for expert insight, practical takeaways, and clarity on the evolving MBC treatment landscape.

In this episode, medical student Kristen Schill interviews Dr. Subha Hanif and Dr. Obada Obaisi, two physicians specializing in cancer rehabilitation. Dr. Hanif completed her PM&R residency at Mary Free Bed Rehabilitation Hospital and her cancer rehabilitation fellowship at the University of Michigan, and she currently practices at Mayo Clinic. Dr. Obaisi completed his PM&R residency at Rush University Medical Center, followed by a cancer rehabilitation fellowship at MD Anderson Cancer Center, and now practices at Rush University. They discuss the role of cancer rehabilitation within multidisciplinary cancer care, the training pathway into the specialty, and how the field continues to evolve. The conversation also highlights opportunities for medical students to get involved and offers practical advice for those considering cancer rehabilitation as a career.

“Would you risk it all for a baby monkey you've never met?”

Love the episode? Send us a text!What if part of what makes cancer so hard isn't just the diagnosis—but the spaces where care happens?In this eye-opening episode of Breast Cancer Conversations, host Laura Carfang explores how hospital design, architecture, and the built environment directly shape the cancer experience, often in ways patients never realize—but deeply feel.Laura is joined by Abbie Clary, Executive Director of Market Strategies and Growth for Health for All, and a nationally recognized leader in healthcare architecture and experience design. With millions of square feet of cancer and healthcare facilities in her portfolio—including projects at Memorial Sloan Kettering, MD Anderson, and the Shirley Ryan AbilityLab—Abbie pulls back the curtain on how hospitals are designed, who they're designed for, and why women are so often treated as the “outlier.”Together, they discuss trauma-informed design, survivorship-centered care, caregiver inclusion, gender bias in medical spaces, and why healing doesn't only happen through medicine—it happens through dignity, control, and environment.In This Episode, We Talk About:Why hospitals and medical spaces are often designed for a “default male”How architecture impacts anxiety, trauma, and healing for cancer patientsWhat trauma-informed design actually looks like in practiceWhy cancer patients experience healthcare differently than other patientsThe importance of designing for repeat visits, not one-time careHow caregivers and loved ones should be treated as part of the care teamWhy dignity, control, and privacy matter as much as efficiencyGender bias in medical design—from gowns to equipment to workflowsWhy women's pain and discomfort are often minimized in healthcareDesigning cancer centers for survivorship, not just treatmentAbout Today's GuestAbbie Clary, FAIA, FACHA, is the Executive Director of Market Strategies and Growth — Health for All. Her work spans some of the most ambitious healthcare projects in the world, including Memorial Sloan Kettering's new Cancer Care Pavilion, MD Anderson Cancer Center's 2030 facilities master plan, and the Shirley Ryan AbilityLab in Chicago.A nationally sought-after speaker and TEDx presenter, Abbie's work focuses on transforming healthcare through strategic, human-centered design—bridging architecture, culture change, patient experience, and health equity. Her mission is simple but radical: design healthcare spaces that actually support healing, dignity, and belonging. Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.

Most of us have been trained to think of treating people as a technical problem. If something hurts, we look for the right drug. If something fails, we look for the right procedure. That picture is incomplete.We've built a system obsessed with fixing bodies, while quietly ignoring the inner worlds of the people living inside them. Their fears, their beliefs, their unanswered prayers, and the meaning they're trying to make of suffering.Illness doesn't just attack organs. It raises questions about God, identity, guilt, fear, and loss of control. And when those questions go unanswered, suffering multiplies, no matter how advanced the treatment plan is.Modern medicine has no real language for this kind of pain. It knows how to measure blood pressure, inflammation, and tumor size, but it doesn't know how to sit with grief, spiritual doubt, uncertainty, and loss.Yet when clinicians slow down enough to listen, something shifts. Patients begin to speak about meaning, about God, about unresolved relationships and fears they've never voiced before.And often, that is where real healing starts — the kind of whole-person healing that restores connection, dignity, and a sense of being spiritually held in the middle of suffering.What if some of the deepest healing doesn't come from doing more, but from being more present? How can clinicians learn to care for the soul as intentionally as they care for the body?In this episode, I speak with Dr. Marvin Delgado Guay, a palliative care specialist at MD Anderson Cancer Center. We talk about what it looks like when medicine includes spiritual care in its everyday practice. We explore why “total pain” includes the soul as much as the body, and how healthcare can become not just a place of treatment, but a space for healing, meaning, and connection with God.Things You'll Learn In This Episode Pain isn't always physicalMany symptoms labeled as “medical” are actually expressions of emotional or spiritual distress. What happens when we treat suffering instead of just symptoms?Fixing vs. healingMedicine is trained to solve problems, but some forms of suffering can't be solved, only witnessed. How does presence become a form of treatment?How spirituality shapes medical decisionsBeliefs about meaning, God, and purpose influence everything from treatment choices to end-of-life care, but are clinicians equipped to address this?The power of the “collective soul” in healthcareWhen doctors, nurses, chaplains, and therapists work as one, care becomes something deeper than specialization. What changes when healing becomes a shared human act?Guest BioDr. Marvin Delgado Guay is an internist and Assistant Professor in the Department of Palliative Care and Rehabilitation Medicine at MD Anderson Cancer Center, where he provides symptom control and supportive care for patients with advanced cancer and their caregivers. He completed his internal medicine training at Michael Reese Hospital in Chicago, followed by a fellowship in Geriatric Medicine at Harvard Medical School, and a clinical and research fellowship in Symptom Control and Palliative Care at MD Anderson. Earlier in his career, he coordinated palliative care services and worked within geriatrics at Lyndon B. Johnson General Hospital through the University of Texas Medical School. Dr. Delgado Guay's work focuses on what medicine often overlooks: the full experience of illness. His research explores physical, psychological, and spiritual distress in patients with serious disease, as well as aging-related issues such as frailty and cognition. He has authored and co-authored multiple peer-reviewed publications on symptom burden and spiritual care in advanced cancer, and is deeply committed to improving quality of...

Dr. Shivani Gupta comes from a family of people with diabetes, generation by generation, where she's seen the after-effects of suffering with chronic metabolic disease.  Her new book, The Inflammation Code (launching, distills 20 years of studying Ayurveda into simple pillars you can apply to prevent the level of inflammation and disease we see today. When people tell her, "I have brain fog, I'm tired, my sleep is off, my digestion's off, I have stubborn weight gain…I guess this is just aging," her reply is, "No, it's not aging, it's inflammaging." We had a really excellent, in-depth conversation that covered a lot of ground, from black pepper and the blood-brain-barrier to our detox experiences in India. I hope you enjoy the podcast! In this podcast, Dr. Gupta and I discuss: Her study of Ayurveda, a 5,000-year-old system from India that taught us the circadian clock, modern science discovered what Ayurveda taught 5,000 years ago about living in rhythm with nature The three doshas or constitutions of Vata (air/ether), Pitta (fire/water), and Kapha (earth/water)—understanding your constitution helps customize your self-care practices and diet The circadian clock in Ayurveda teaches that 10:00 to 2:00 PM is Pitta (fire) time, when you're most focused and energetic, and meant to eat your biggest meal 10:00 PM to 2:00 AM is the most important time to be asleep, when Pitta fire cleans and clears inflammation, the lymphatic system, and the glymphatic system (lymphatic system of the brain) Vata people are always in motion and prefer jobs where they don't sit still—they're endurance athletes who can run through the day on coffee, green juice, and crackers (but their homework is three square meals) Pitta people are fiery, passionate leaders who tend to crave hot, oily, spicy fried food…but that's the one thing they shouldn't eat because their digestive fire is already like a bonfire! Kapha people are sturdy, strong, and very grounded, but can struggle with sluggish metabolism, low mood or depression, getting stuck, or not wanting to create change Black pepper increases curcumin absorption by 2,000%—scientists at MD Anderson Cancer Center discovered this, which is why traditional Indian cooking always uses turmeric with black pepper What it feels like to experience a Panchakarma detox in India: "massage that feels like abuse" with paper thongs—Dr. Gupta says, "I can't believe you're allowed to do this to me and I'm paying for it" (both she and I had this experience!) Mental inflammation is the stress we create when forcing ourselves to be healthy; if you force workouts, force protein, force intermittent fasting, the stress alone causes the inflammation you're trying to prevent

You're about to biopsy a renal lesion; should you ablate at the same time? In this episode of the BackTable Podcast, host Michael Barraza talks with Dr. Steven Huang from MD Anderson Cancer Center about building an efficient and effective renal biopsy and ablation service line. --- This podcast is supported by: Varian IntelliBlatehttps://www.varian.com/products/interventional-solutions/microwave-ablation-solutions --- SYNPOSIS Dr. Huang first covers referral patterns and the typical pathway that patients take to end up in his clinic. The discussion covers the types of lesions he treats, imaging requirements, and criteria for patient eligibility. He emphasizes the importance of shared decision making when deciding between active surveillance, interventional treatment, and partial nephrectomy. Dr. Huang explains his preferred procedural approach and ablation modalities, including cryo, microwave (MWA), and radiofrequency ablation (RFA). He shares his experiences with challenging cases and integrating new technologies like histotripsy and the Siemens interventional package. They also discuss the possibility of a preoperative embolization for larger lesions that could be susceptible to the heat sink effect. Both experts emphasize the importance of collaboration with urologists and ensuring patient safety and expectations. They also touch on the future of the field, discussing the use of AI and robotics. --- TIMESTAMPS 00:00 - Introduction 02:17 - Training Programs at MD Anderson03:23 - Referral Patterns for Renal Ablations07:25 - Patient Management and Virtual Consultations10:59 - Ablation Techniques and Device Selection26:44 - Challenges and Complications27:25 - Approach to Lesions Near Renal Vasculature28:02 - Patient Expectations and Urologist Collaboration33:26 - Post-Procedure Care and Patient Recovery35:30 - Managing Recurrences and Multiple RCCs47:17 - Closing Remarks

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option. Episode Highlights: • Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments. • In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics. • Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects. • Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations. • Practical considerations for administering these treatments in both inpatient and outpatient settings. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals! #AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

Something New!  For HR teams who discuss this podcast in their team meetings, we've created a discussion starter PDF to help guide your conversation. Download it here https://goodmorninghr.com/EP237  In episode 237, Coffey and DeDe Church discuss recent news items about how shifting economic conditions, technology, and leadership gaps are reshaping the employment landscape.  They discuss the realities of a “low-hire, low-fire” labor market; dehumanizing hiring processes and AI-driven recruiting tools; challenges facing early-career workers and liberal arts graduates; emerging roles created by artificial intelligence; the growing importance of soft skills like problem solving and communication; workforce restructuring, layoffs, and job hugging; employee disengagement and the great detachment; why strong frontline workers often struggle as supervisors; the risks of promoting without leadership training; transparency, feedback, and promotion decisions; and how kindness, accountability, and continuous feedback drive engagement.  Good Morning, HR is brought to you by Imperative—Bulletproof Background Checks. For more information about our commitment to quality and excellent customer service, visit us at https://imperativeinfo.com.   If you are an HRCI or SHRM-certified professional, this episode of Good Morning, HR has been pre-approved for three quarters of a recertification credit. To obtain the recertification information for this episode, visit https://goodmorninghr.com.   Media mentioned in this podcast:  From AI bubble fears to the job market's ‘Great Freeze': Economists answer your biggest questions about 2026  Private-Sector Hiring Turned Positive in December After November Losses   Private Hiring Sank in November, ADP Says  US Bureau of Labor Statistics Occupational Outlook Handbook: Fastest Growing Occupations  The 2026 Job Market Outlook: Where the Jobs Are  Economists Are Studying the Slowing Job Market—and Feeling It Themselves  When Good Frontline Workers Make Bad Supervisors  Is Your Leadership Style Too Nice? The Friendship Recession: The Lost Art of Connecting Use Situation-Behavior-Impact (SBI)™ to Understand Intent  About our Guest:  DeDe Church is an attorney, employee relations counselor, workplace and University investigator, and nationally recognized trainer with more than 30 years of experience. She has trained thousands of employees and managers on how to create a productive, respectful culture for clients ranging from Fortune 50 companies to her favorite local pizza shop. Known for her humor and practicality, DeDe is often invited and then re-invited to deliver her high-energy workshops at distinguished conferences and to create videos for employee onboarding and annual training.  As an expert investigator, DeDe relies upon a depth of knowledge to find the facts without causing unnecessary disturbances. Witnesses often say they feel at ease when talking with her because of her approachable nature. In addition, DeDe is often retained to review investigation procedures and to train in-house HR and University professionals on investigation best practices. In recognition of her skills, DeDe has been retained to testify as an expert witness in employment cases more than 20 times by organizations including Uber, BP, and MD Anderson Cancer Center.  DeDe is a former Senior Assistant Attorney General for the State of Texas in the Civil Rights/General Litigation Division. During almost seven years there, she advised dozens of state agencies on the proper response to employee complaints, represented the State in over 30 trials involving discrimination in the workplace, and successfully argued before the Fifth Circuit Court of Appeals and the Texas Supreme Court. DeDe received the prestigious Presidential Citation from the President of the Texas State Bar in recognition of outstanding service to the citizens of Texas. Her Bachelor of Arts degree is from Louisiana State University, magna cum laude, and she received a Doctorate of Jurisprudence with Honors from the University of North Carolina School of Law in Chapel Hill, North Carolina.  DeDe Church can be reached at www.dedechurch.com https://www.linkedin.com/in/dede-wilburn-church-a71b748/  About Mike Coffey:  Mike Coffey is an entrepreneur, licensed private investigator, business strategist, HR consultant, and registered yoga teacher. In 1999, he founded Imperative, a background investigations and due diligence firm helping risk-averse clients make well-informed decisions about the people they involve in their business. Imperative delivers in-depth employment background investigations, know-your-customer and anti-money laundering compliance, and due diligence investigations to more than 300 risk-averse corporate clients across the US, and, through its PFC Caregiver & Household Screening brand, many more private estates, family offices, and personal service agencies. Imperative has been named a Best Places to Work, the Texas Association of Business' small business of the year, and is accredited by the Professional Background Screening Association.  Mike shares his insight from 25+ years of HR-entrepreneurship on the Good Morning, HR podcast, where each week he talks to business leaders about bringing people together to create value for customers, shareholders, and community. Mike has been rec...

Today, I am excited to speak with Dr. Carl Robinson, Founding Partner at Vantage Leadership Consulting. Carl is a licensed clinical psychologist who has spent the better part of the last 35 years assisting executives and families in preparing for and navigating career-defining moments. His clientele is broad and far-reaching, ranging from non-profit organizations to the Fortune 100, and includes names such as the Federal Reserve System, MD Anderson Cancer Center, Whirlpool, Steel Dynamics, The Hyatt Corporation, and many more. Carl is a highly regarded public speaker, who has authored a number of articles and has frequently been interviewed by various business publications, including the Wall Street Journal. He is a longtime friend, collaborator, and former member of the Advisory Board of FOX. Succession is arguably the most important evergreen topic on the minds of enterprise families and their family offices. Carl shares his views on what is required for success in successions among UHNW families and family offices and talks about the importance of talent assessment as families undertake leadership and ownership succession journeys. Carl offers practical advice for the older generation and those in leadership who are looking to transition control, responsibility, and ownership to the next generation. He also provides invaluable tips and suggestions for the rising gen and those who are poised to step into leadership and fill the shoes of their parents and predecessors. Don't miss this highly instructive conversation with one of the longest-serving, deeply experienced advisor and coach to multigenerational enterprises and family leaders.

This bonus episode is the audio from a Breastcancer.org webinar. Follow-up care after breast cancer is essential. Getting good follow-up care can make a big difference in your long-term health and quality of life. In this Breastcancer.org webinar, you'll find out how often you should see your oncologist after your treatment ends and get other practical advice from our expert panelists and patient advocates. Watch the webinar to get expert advice from the panelists, including:  Marisa C. Weiss, MDChief Medical Officer and Founder, Breastcancer.org Hoda Badr, PhDProfessor, Department of Medicine, Baylor College of Medicine Fumiko Chino, MDRadiation Oncologist, Memorial Sloan Kettering Cancer Center Evelyn Robles-Rodríguez, DNP, APN, AOCNDirector of Outreach, Prevention, and Survivorship, MD Anderson Cancer Center at Cooper Erin Roesch, MDBreast Medical Oncologist, Cleveland Clinic Megan-Claire ChaseBreast Cancer Program Director, SHARE Cancer SupportPatient Advocate Amanda HelmsPatient Advocate Kate RosenblumPatient Advocate Loriana Hernandez-AldamaTwo-Time Cancer Survivor, Award-winning Journalist, Author

Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article "Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality," highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at EOL (end of life) and the need for better communication between oncologists and patients regarding expected risk and benefits of such treatments to properly align goals-of-care. TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. Maureen Canavan, epidemiologist and associate research scientist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; and by Dr. Kerin Adelson, Chief Quality and Value Officer, medical oncologist, and clinical researcher on health services and clinical care delivery at MD Anderson Cancer Center. In the manuscript "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." that you recently published in the JCO, you performed an analysis that included more than 30,000 older adults in the SEER-Medicare database, and you observed that 7.6% of these patients received any systemic anticancer medication within 30 days of death. So, I wanted you to explain why you thought that this was a priority right now, and whether there was any previous data that was published in the literature, and if you think that there was any significant gap in the literature that led you to the research you just published. Dr. Kerin Adelson: We have published a series of articles looking at real-world trends  in patterns of care, particularly related to systemic anticancer therapy at the end of life. This has been gaining increasing focus in recent years because of the understanding that when patients stay on systemic anticancer therapy, that is often a surrogate for a lack of goal-concordant care. So, patients who continue to receive systemic therapy have worse quality of life, are more likely generally to have a medicalized death, and less likely to use hospice. And what our prior work has shown is that more and more we are seeing patients using immunotherapies and targeted therapies towards the end of life. No prior work had really comprehensively examined whether these novel therapies were associated with those same patterns of care increases in acute care utilization and decreases in hospice. Dr. Davide Soldato: So basically, the data that we had up until that point was mostly with cytotoxic chemotherapy, and the emergence of this new treatment, which frequently are thought to be less toxic and so less problematic also in the end of life, led to this research. Is that correct? Dr. Kerin Adelson: Correct. Dr. Maureen Canavan: I would also build on that. I think that as the landscape of cancer care changes, it is important to really understand the availability of treatments, but then also, as Kerin noted, it is important to focus on goal-concordant care. We have established literature, studies we have done and some other studies that have looked at cytotoxic chemotherapy, but with the emergence of these targeted therapies, we really did not know a few things. We did not know the rates of utilization in a large national population, and how that was associated with these elements of medicalized death like ED use, hospitalizations, acute care use. So this was really a question that we had going into it. How can we expand the knowledge base so that both patients and providers can be more cognizant when thinking about goals of care conversations and ensuring that that is in place? Dr. Kerin Adelson: And our work has kind of evolved to answer some critical questions. So, one of our early papers looked at different rates of systemic anticancer therapy at the end of life, and that is where we showed that we were seeing a lot more immunotherapy and targeted therapy. And then we asked the question, well, oncologists generally when they give these treatments, they are hoping that those treatments are going to work and help the patients live longer. So we did another paper where we actually looked at practices who were more aggressive near the end of life and whether they had better overall survival than practices that were less aggressive, accounting for the fact that there could be populations of patients who benefited. And in fact, we showed there was no survival difference. So then this paper sort of answered the question: Well, if it is not having benefit, is this treatment actually doing harm? And this study gets at that question: What are the harms of continuing patients on therapy past the point of benefit? Dr. Maureen Canavan: And I think building off of that, the use of the SEER-Medicare database is a quite robust database. So in this, we have very specific data we can track. We can track the exact type of treatment they had, you know, was it a targeted therapy? Was it immunotherapy? So looking at those subclasses of therapy. We were also able to directly link it within that time frame to the acute care utilization, a limitation that we had in some of our previous work that that data was not always available. So it is more focused in the sense that we were looking at older adults, so patients 66 years of age and older, but we were able to get those individual metrics. So to Kerin's point, we did not see the survival benefit. What do we see then for these medicalized death elements? So the higher rates of all of them across the board. Dr. Davide Soldato: So coming back to the cohort and to the data that you utilized, Dr. Canavan mentioned the use of the SEER system to analyze these data. You already mentioned that you included mostly older adults, so those aged 66 and more. And also there was a little bit of restriction regarding the fact that the patient needed to be covered by Medicare in the last year of death concerning Part A and Part B, and the last 30 days from death concerning Part D. So I just wanted to ask a little bit of a question regarding these findings and whether you think that we also need additional work, especially in the younger population because I think it is something that all of us who work in oncology have seen. The aggressiveness, and this is also something that you showed in your data, tends to increase as the age of the patient tends to decrease. So we tend to be more aggressive towards younger patients. So just a comment on that on the population and generalizability of the findings. Dr. Maureen Canavan: Yeah, I will start with the data question element. Thank you. I think there are a few things to point out for that. So in terms of the restriction to ensure that they had continuous Part D coverage, that was necessary for us to track their oral medication use during that time. So kind of an easy response. The Part A, Part B requirement, it is actually pretty widely used in studies of SEER-Medicare data, and that is you want to establish the patient population, that they are not getting treated with another insurance provider in some way that you are not able to track. So that ensures that we can track not only their systemic anticancer therapy use but also when we are trying to make sure that we are controlling for confounders like chronic conditions and stuff, we are able to track the presence of chronic conditions. So we wanted to make sure we were not biasing the data, so I think that was an important consideration. You do point out very wisely that there are then limitations with the generalizability, and I think we would be lacking if we did not account for that. But I think it is important to establish this baseline relationship association, and then you can step out, we will say, to more diverse populations. So I think we could potentially maybe try to relax the timeline to see if people that might have influx in and out of the Medicare system are still seeing those same rates. I think it is likely they would. But I think to the bigger point that you bring up is that establishing this within the older adults where, you know, we do see as they get older maybe less rates of systemic therapy, extending it to the younger population. There is a challenge with that in that just that data is not available to the robust level that SEER-Medicare is. Both Kerin and I have noted that there is the possibility to look within one specific insurance provider type. Again, recognizing the limitations of the generalizability, but always slowly pushing the needle, finding out more about younger adult populations. And I think this is maybe in an ideal world, but setting the precedent that we really do need to track this on a national scale within younger adults because they do have the need. We do see these higher rates of utilization, and really making sure again with the mindset always of the best interest of patients and the most informative to providers in how we are looking at care. So I think generalizability is definitely a goal. However, there are limitations of the availability of data for younger populations and I think that they are a necessary restraint that all researchers should acknowledge. Dr. Kerin Adelson: Yeah, I think it is important for our audience to understand that health services research and large database research is really limited by what databases are available and what are the characteristics of those databases. So we have done a lot of work in an electronic health record database, and there you can get certain kinds of granularity that you may not be able to get in a payer or a claims-based database. But what you do not get is that comprehensive look at, say, what happens if a patient goes to another practice. Claims-based databases offer you that, but research on US populations is limited by our payment system. So when you look at younger patients, there are so many different insurance companies that when you are trying to get that comprehensive view, it can be hard or very expensive actually. These commercial insurers will sell their data to different databases. So for us, the largest single payer in the United States is the US government, and that is for patients who are over age 65, and that is why you see lots of US-based studies done in the Medicare population. Interestingly, a recent paper by a Canadian group showed very, very similar patterns. It was a significantly smaller study but, right, Canada is a single-payer system and so they were able to really look at all ages, and we did see the same patterns of care in a different payment system. Dr. Davide Soldato: Going back a little bit to the type of treatments that were observed in your manuscript, so we start from a 7.6% of patients who received any type of systemic anticancer therapy within 30 days from death. And when we split the different categories that you analyzed, which I think is a very strong aspect of your manuscript, we see that more or less 50% of the patients received chemotherapy, 20% more or less received immunotherapy, more or less 20% targeted therapy, and then there is a combination of those agents. So just wanted to have a little bit of your opinion compared also to the data that you already published and that you mentioned before. Was this in line with previous data? Was there anything surprising about this? We saw a little bit of a raise in the use of immunotherapy and targeted therapy as you were saying, but still, there is a very high proportion of chemotherapy, 50%. Dr. Kerin Adelson: So I think that really, really reflects the time period in which we studied where immunotherapies were gaining ground. There was tons of excitement and we were seeing this shift. I bet if we do the same study in five years that chemotherapy percent may even go down to half, and we are going to see more and more targeted and immunotherapies, and that is just reflecting the pattern of drug discovery that we are seeing. Dr. Davide Soldato: Coming to the real question that you wanted to answer with this manuscript, so is systemic anticancer therapy associated with worse outcomes in terms of healthcare utilization and use of hospice resources? Was there any hint that for example immunotherapy was related to less of these adverse outcomes? Dr. Kerin Adelson: So I will be honest, I was a little bit surprised that the combination of chemotherapy and immunotherapy was that much more strongly correlated with acute care use at the end of life. You know, I had really thought most likely that what we would see were similar rates. And we did. Each different type of systemic anticancer therapy was associated with significantly higher odds of ending up in the hospital, going to the ICU, dying in the hospital, going to the ED. But that group that got dual therapy was that much higher, you know, over three times the risk. And that surprised me because what it suggested is that there is likely a component of treatment toxicity that is leading to some of the acute care use. It is not simply just a constellation of patients who have not yet transitioned towards hospice or palliative care or end-of-life care who are then more likely to end up in the hospital. But the fact that we see a difference between, say, single-agent immunotherapy and dual combination with chemotherapy does suggest that the treatments are actually contributing to some of what we are seeing. Dr. Davide Soldato: But still, all of the treatments that you evaluated were still associated with higher healthcare utilization. Like there was no signal that, for example, giving immunotherapy at the end of life was not associated with these adverse outcomes. Correct? Dr. Kerin Adelson: Correct. And you will find oncologists out there who will say, actually, these treatments are so good that they might actually lower rates of hospitalization because they keep patients healthy. And certainly, that may be true upstream or earlier in the course of disease, but at the end of life, any form of systemic anticancer therapy is really a surrogate marker for lack of transition towards what is likely appropriate end-of-life therapy. And I just want to point out that time spent in the hospital, going back and forth to invasive procedures, going to the intensive care unit, even going back and forth to an infusion center, that is time that is not spent at home with loved ones for people who have very little time left to live. Dr. Davide Soldato: Thank you very much. That was exactly the point that I wanted you to stress because I think it is really the most important message that we can get as oncologists from this manuscript. Like there is no treatment that is not associated with potentially harming our patient and, as you were saying, taking off time with loved ones in a critical period of the life of these individuals who have been diagnosed and treated for cancer. So, basically what we saw in the paper was a 7.65% utilization of systemic anticancer therapy. And I might imagine that for some oncologists or for some hematologists that might not actually be that much. Like they could potentially say, "Okay, but it is like 7%, it is not that high. I would have expected something higher." So I just wanted a little bit of perspective regarding also quality metrics that we have available for these types of indicators at end-of-life care. What would be the appropriate percentage of people receiving any type of treatment within 30 days from death? Dr. Maureen Canavan: A couple caveats, as a data person I always like to give those. This was among all cancer patients, so not necessarily patients that had been on active treatment. So I think that number was actually quite lower than when we looked in another study about patients that had chemo within the last year, so on, you know, active treatment. So I think that is an element to take into consideration is that those numbers will vary based on who your denominator population is. So that is important to consider. Additionally, the National Quality Forum, they call for reducing rates of systemic therapy at end of life. But I think they, similar to how I would be, are cautious to point out this is the exact number, or it should be zero. Because there are cases where you have to go in line with patient preferences. And if a patient is very adamant that they want to continue treatment, that needs to be a decision that comes between them and their provider. So, you know, the zero, though sounding ideal to us who want to encourage transitions and encourage goals of care conversation is a nice number, it is not a realistic. So, to evade your question completely, I do not think there is a set number. But the goal is to make sure that both patients, providers, everyone is informed and is making the best holistic decision. So there is this natural tendency, I think, to keep fighting both for the patient and the provider to try to beat something, but recognizing the point at which we are beyond a benefit of treatment and what would be most beneficial to the patient in terms of getting back to that idea of, you know, the time with their families and whatnot. So is the number zero? No. Could it probably be lower than we have? I think yes, definitely. Dr. Kerin Adelson: I completely agree with everything Dr. Canavan said. I think one of the other challenges is that this data isn't being tracked and publicly reported across the world. And so what that optimal rate is, is a little unclear. We see different rates also depending on the population included. So one of the things Dr. Canavan said is our database included patients who were likely treated long ago for cancer and cured of their cancer. So they were less likely to die on systemic therapy. But until everybody starts tracking and reporting, it is really hard to know where we are as a country or really as a global population, and then what are the bars that we want to achieve in driving down the rates. I think some data shows that probably something in the range of 10% or below, you know, for patients who have more active cancer is probably where we should be going and driving towards. But until we have more public reporting of these metrics and consistency in how we measure them, it is really hard to come up with a single number. Dr. Davide Soldato: I have the impression that sometimes there is also a little bit of difficulty for the oncologist or the hematologist to really understand who are the patients who are approaching end of life. So there has been some data and you also report some of them in the discussion of the manuscript regarding, for example, prompts inside of the electronic health records or the use of artificial intelligence to try to predict what is the disease course. So just wanted a little bit of perspective if you think that these tools could potentially be helpful and if you think that we will be able at a certain point to implement them in routine clinical care. Dr. Kerin Adelson: I have been working on trying to do this actually at MD Anderson and coming up with a really reliable data tool that will tell us who are the patients who are going to die in short order after receiving systemic anticancer therapy. And it is not that easy, I will say. So, you know, I think we all want this amazing machine learning model that is incredibly reliable. But like any statistical test, there are problems, right? So a very sensitive test that is going to identify high, high risk of dying at the end of life is going to be compromised by false positives. And when an oncologist knows that the test might be a false positive, it becomes very hard for them to take action on it. Similarly, you know, a very, very specific test is going to be compromised by false negatives. So in that case, you could end up having patients who are at risk for dying and still treating them with chemotherapy. And so, you know, I think in the end we need some tools. It will be great if machine learning becomes very reliable and we have the right structured data elements in our electronic health records to give these reliable prediction tools. But I think there are some basic things that we all know, and those are the markers of chronicity of cancer. So patients who have had multiple lines of therapy already, right? Past the point of clinical trial benefit. Patients who have lost significant amounts of weight. Patients who are not getting out of bed and have worse performance status. Patients who are increasingly confused, right? And not mentally engaging the way they did previously. Those markers have been shown in numerous publications by a colleague of mine, David Hui and others, to really be pretty strong predictors, and they resonate with clinicians more than a machine learning score might. You know, I think when clinicians do not understand what the elements in a machine learning tool are, they are less likely to trust it and more likely to say, "Oh, it is a false positive or a false negative." But very few clinicians can argue against the fact that the patient who hasn't gotten out of bed in two weeks is somebody who is less likely to benefit. Dr. Davide Soldato: Dr. Adelson, I would like to close this podcast and I would like to thank you again for joining us today. Dr. Maureen Canavan: Thank you so much. Dr. Kerin Adelson: Thank you so much for having us. Dr. Davide Soldato: Dr. Canavan, Dr. Adelson, we appreciate you sharing more on your JCO article titled "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can f ind all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Disclosures Kerin AdelsonStock and Other Ownership Interests: Carrum Health Consulting or Advisory Role: Abbvie, Quantum Health, Gilead SciencesPatents, Royalties, Other Intellectual Property: Genentech Other Relationship: Genentech/Roche Employment: Emilio Health/Brightline Health(An Immediate Family Member) Stock and Other Ownership Interests: Emilio Health/Brightline Health, Lyra Health (An Immediate Family Member)

Send us a textWhat if cancer didn't have to be eradicated, but could be remembered, monitored, and controlled by the immune system itself?In this episode of Causes or Cures, Dr. Eeks speaks with Dr. Zachary Hartman, the lead researcher who revisited an extraordinary breast cancer vaccine trial conducted over 20 years ago. The trial involved a small group of women with advanced breast cancer. Women who, remarkably, are all still alive today.By analyzing their blood decades later, the research team discovered that these women still carried immune cells capable of recognizing their cancer, suggesting durable immune memory lasting more than two decades. (Study link here.)We discuss:The original breast cancer vaccine trial and what it was designed to do, in plain languageWhat it was like to discover that the women from the trial was still alive more than 20 years laterHow the immune systems of these women continued to recognize cancer cells long after the trialWhat CD27-positive immune cells are and why they matter, explained simplyWhy helper CD4 T cells may be just as important, or more important, than killer CD8 T cells when it comes to cancerWhat happened when researchers combined a CD27-boosting antibody with a cancer vaccine in miceWhat surprised the research team mostThe challenges of translating findings from mice to human trialsWhether cancer could someday be managed long-term by the immune systemHow generalizable this immune memory might be across different cancersWhat this research could mean for how we think about vaccines in a post-pandemic worldThe one key message the researcher hopes the public takes awayWhat's next in this line of researchThis episode offers a rare, hopeful (but scientifically grounded) look at how the immune system may be capable of remembering cancer for decades. Guest Bio: Dr. Zachary C. Hartman is an Associate Professor at Duke University in the Departments of Surgery, Pathology, and Integrative Immunobiology, where he also serves as Director of the Center for Applied Therapeutics and is a member of the Cellular and Molecular Biology and Genetics and Genomics programs. He earned his undergraduate degree from Northwestern University and completed his PhD at Duke University, followed by postdoctoral training in tumor immunology and breast oncology at Duke and the MD Anderson Cancer Center. In 2012, Dr. Hartman returned to Duke to establish a research program focused on tumor immunology and the development of cancer immunotherapies, including therapeutic vaccines, immune agonists, checkpoint inhibitors, antibody-based therapies, and strategies to stimulate anti-tumor immune responses.  Work with me? Perhaps we are a good match. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.Or X.OnSupport the show

In this episode of Off Script, we continue our conversation with Jason Bock, co-founder and CEO of CTMC, diving deeper into the operational and manufacturing challenges shaping the future of curative cell therapies. Jason discusses how CTMC—through its partnership with MD Anderson Cancer Center—is eliminating inefficiencies across development timelines to significantly accelerate clinical progress without increasing risk. He also shares a forward-looking perspective on how cell therapies could one day be ordered and delivered like traditional pharmaceuticals, and what scientific, regulatory, and manufacturing innovations will be required to make that vision a reality.

My conversation with Dr Emanuel begins at about 34 minutes Subscribe and Watch Interviews LIVE : On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous soul In Eat Your Ice Cream, renowned health expert Dr. Ezekiel J. Emanuel argues that life is not a competition to live the longest, and that "wellness" shouldn't be difficult; it should be an invisible part of one's lifestyle that yields maximum health benefits with the least work Ezekiel J. Emanuel, MD, PhD, is the Vice Provost for Global Initiatives, the Co-Director of the Healthcare Transformation Institute, and the Diane v.S. Levy and Robert M. Levy University Professor at the University of Pennsylvania Perelman School of Medicine. Emanuel is an oncologist and world leader in health policy and bioethics. He is a Special Advisor to the Director General of the World Health Organization, Senior Fellow at the Center for American Progress, and member of the Council on Foreign Relations.  He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August of 2011. From 2009 to 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. In this role, he was instrumental in drafting the Affordable Care Act (ACA). Emanuel also served on the Biden-Harris Transition Covid Advisory Board. Dr. Emanuel is the most widely cited bioethicist in history.  He has over 350 publications and has authored or edited 15 books. His recent publications include the books Which Country Has the World's Best Health Care (2020), Prescription for the Future (2017), Reinventing American Health Care: How the Affordable Care Act Will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System (2014) and Brothers Emanuel: A Memoir of an American Family (2013). In 2008, he published Healthcare, Guaranteed: A Simple, Secure Solution for America, which included his own recommendations for health care reform. Dr. Emanuel regularly contributes to the New York Times, the Washington Post, the Wall Street Journal, The Atlantic, and often appears on BBC, NPR, CNN, MSNBC and other media outlets. He has received numerous awards including election to the National Academy of Medicine, the American Academy of Arts and Sciences, the Association of American Physicians, and the Royal College of Medicine (UK). He has been named a Dan David Prize Laureate in Bioethics, and is a recipient of the AMA-Burroughs Wellcome Leadership Award, the Public Service Award from the American Society of Clinical Oncology, Lifetime Achievement Award from the American Society of Bioethics and Humanities, the Robert Wood Johnson Foundation David E. Rogers Award, President's Medal for Social Justice Roosevelt University, and the John Mendelsohn Award from the MD Anderson Cancer Center. Dr. Emanuel has received honorary degrees from Icahn School of Medicine at Mount Sinai, Union Graduate College, the Medical College of Wisconsin, and Macalester College. In 2023, he became a Guggenheim Fellow. Dr. Emanuel is a graduate of Amherst College. He holds a M.Sc. from Oxford University in Biochemistry, and received his M.D. from Harvard Medical School and his Ph.D. in political philosophy from Harvard University. On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete   Listen rate and review on Apple Podcasts Listen rate and review on Spotify Pete On Instagram Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on Twitter Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo  

Autologous cell therapies have shown the promise of single-dose, curative treatments for patients with advanced cancers. But even with major scientific and regulatory progress, the field now faces its toughest challenge yet: achieving sustainable, scalable manufacturing for highly personalized therapies. In this episode of Off Script, we spoke with Jason Bock, co-founder and CEO of CTMC, a purpose-driven cell therapy accelerator. Jason discusses why scale remains the central barrier for autologous therapies, the significance of CTMC's partnership with MD Anderson Cancer Center, and how fit-for-purpose manufacturing models can shorten vein-to-vein time and bring transformative treatments to patients faster.

Edward M. Schaeffer, MD, PhD, moderates a thoughtful conversation with two former Northwestern Urology residents, Richard Matulewicz, MD, MSCI, MS, urologic surgeon at Memorial Sloan Kettering Cancer Center, and Neema Navai, MD, MHCM, professor and chair of the department of urology and special advisor to the chief physician executive for care development at MD Anderson Cancer Center. Together, they share insights from their professional journeys, explore the evolving landscape of urologic care and discuss how their experiences have shaped their career paths and approach to patient care.

Steve Austin has been a pastor and senior director at Lakewood Church in Houston, Texas - the largest church in America - for over 20 years. He has overseen 24 ministries and 40 adult Bible classes and has been a frequent speaker. Steve has ministered to thousands of sick people and their families in the largest medical center in the world - the Texas Medical Center in Houston - and did hospital chaplaincy training at MD Anderson Cancer Center, the world's top cancer center. He is the President and Executive Director of Living Hope Chaplaincy, a nonprofit organization that trains and mobilizes volunteers to provide spiritual care to hospital patients, their families, and healthcare workers.STEVE'S BOOK:https://a.co/d/fAQc9sX

Dr. Bailey arrives in Oxford after three years with Vanderbilt athletics. Additionally, Dr. Bailey has spent the last two years with Expansive Insight, a private practice focused on a broad range of mental health counseling, intervention and psychotherapy measures. "Oxford has already shown its kindness to my family," Bailey said. "I'm excited about serving in the 'Sip and being a part of the athletics family here at Ole Miss. I think being a sport psychologist is the coolest job in the world. It's truly a calling to work in mental health and sport performance, and I'm glad to serve the athletes here at Ole Miss." Prior to his time at Vanderbilt, Dr. Bailey acquired a wealth of experience in counseling and mental health treatment, most recently serving as a Predoctoral Psychology Intern for Duke University's CAPS program during the 2021-22 academic year. Further experience came with the Austin, Texas Fire Department and Emergency Medical Services unit, the 'Center for Relationships', a community wellness center in Austin, MD Anderson Cancer Center, work with persons who are incarcerated, and the University of Texas Counseling and Mental Health Center. Additionally, Dr. Bailey has spent the last 10 years providing counseling services to local clients, including children, adolescents, and adults presenting with depression, anxiety, grief and loss, PTSD, OCD, marital and relationship issues, body image, sports and fitness and much more. Dr. Bailey is a licensed psychologist, licensed social worker, and a certified mental performance consultant. Dr. Bailey is also a lifelong athlete and sports fan. A native of Austin, Texas, Dr. Bailey holds a doctorate in counseling psychology from the University of Texas at Austin in 2022. Dr. Bailey also earned his master's of science in social work and bachelor's degree in psychology at Texas in 2012 and 2009, respectively.

Isabel González entrevista a la Dra. Silvia Pérez Rodrigo.

Love the episode? Send us a text!Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast CancerIn this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what's new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option.Dr. Layman walks us through the VIKTORIA-1 trial, a phase III study of a new IV drug (genitolasib, “G” for short) that targets the PAM pathway, which cancer cells often use to grow and outsmart standard hormone therapy. She explains, in plain language, what PIC3CA mutations are, what “wild-type” means, and why this trial is so exciting even for people without a PIC3CA mutation.You'll hear:Why ER-positive breast cancer is the most common subtype—and still a major driver of metastatic diseaseHow clinical trials are designed, and why they're often most powerful earlier in treatment (not only when “nothing else is left”)A clear explanation of the VIKTORIA-1 study design: who was eligible, how the drug is given, and what the results showedWhat “progression-free survival” means and how adding “G” changed the numbers compared to standard therapy aloneHonest talk about side effects (mouth sores, rash, blood sugar changes), and how teams are preventing and managing themHow patients can look up trials like VIKTORIA-1 and VIKTORIA-2 on ClinicalTrials.gov and bring these conversations back to their own oncologistsWhether you're living with ER-positive metastatic breast cancer, supporting someone who is, or simply trying to understand the rapidly evolving science, this episode offers both education and hope.Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday!

Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company's evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase for MSI-high cancers to a highly selective SIK2 program and GLP-1–adjacent strategies focused on body composition, Abbas details how Nimbus balances rigor, speed, and capital efficiency. He shares candid lessons from pausing and later resurrecting AMPK beta in partnership with Eli Lilly, the decision to remain modality-agnostic but small-molecule-centric, and the importance of knowing when not to chase the latest fad. Throughout, Abbas returns to a consistent theme: success at Nimbus comes from disciplined target selection, deep collaboration, and a culture that empowers teams to make hard calls in service of patients rather than headlines. Biography: Abbas Kazimi is the Chief Executive Officer of Nimbus Therapeutics. Previously, he served as Chief Business Officer, leading the company's strategic and corporate development efforts while overseeing business operations. Since joining Nimbus in 2014, he has helped raise over $630 million in equity financing and led transactions totaling more than $8 billion. Notably, Mr. Kazimi spearheaded the $6 billion sale of Nimbus's TYK2 program to Takeda, the $1.2 billion sale of its NASH (ACC) program to Gilead, and multiple licensing deals exceeding $1.5 billion with partners such as Genentech, Celgene/Roche, and Eli Lilly. Under his leadership, Nimbus has advanced four programs into the clinic, returned over $4 billion to investors, and continues to expand its computational drug discovery and clinical development capabilities. In 2025, Mr. Kazimi joined the board of Unnatural Products (UNP), a biotech company pioneering orally delivered macrocyclic peptides to tackle previously undruggable targets. He also serves on the Editorial Advisory Board for In Vivo magazine, a leading publication offering strategic insights and analysis of the pharmaceutical, biotechnology, medtech, and consumer health industries. Along with his family, he established the Kazimi Family Endowment for Data Science in Oncology at MD Anderson Cancer Center. This endowment reflects their personal commitment to philanthropy and their vision for revolutionizing cancer treatment through data-driven innovation. At the core of Mr. Kazimi's leadership is a deep sense of purpose—one that seeks to change the trajectory of medical diagnoses where options are limited. The ability to give patients, prescribers, and families a new outlook on life is a powerful responsibility—and one he knows the biopharmaceutical sector has the ability to fulfill. Before Nimbus, he was at Extera Partners, LLC (formerly PureTech Development, LLC), where he provided strategic advisory, supported fundraising, and executed numerous business development transactions. Earlier in his career, he was with JSB-Partners, LP, a specialized investment banking and advisory firm serving biotech and pharmaceutical companies. Mr. Kazimi holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University.

In this episode, Dane Groeneveld speaks with Mickie DeVeau, Director of the Leadership Institute at MD Anderson Cancer Center, about how one of the world's leading healthcare organizations builds leadership capacity at every level.Mickie shares how MD Anderson's coaching culture empowers employees—from physicians to administrative staff—to lead with empathy, accountability, and purpose. Their conversation explores how structured development, shared responsibility, and authentic connection help make “Making Cancer History” more than a tagline.

Have you ever gotten up for a full day's work in a haunted coal mine and thought, "Boy, I really hope that bird in a cage doesn't stop singing and doom us all"? No? Then you clearly weren't with the RPGBOT crew in Part 2 of our Old Gods of Appalachia charity stream—where coal dust has claws, headlamps are your best friend, and it turns out you can get shot-in-the-foot vibes without ever firing a gun. Buckle up, y'all. Things are getting deep, dark, and very dusty. Support MD Anderson Cancer Research Before we go further, remember: this campaign was part of a live charity event supporting MD Anderson Cancer Center, one of the top cancer hospitals in the world. Their mission is simple but critical: end cancer for patients everywhere through advanced research, treatment, and compassionate care. You can still make a difference. Donate today at https://mdanderson.donordrive.com/participants/9351 — every dollar helps bring hope, healing, and lifesaving treatment to real people in the fight for their lives. Previously, on the RPGBOT charity stream: Jessie and Isaiah arrived in Williams Holler—an Appalachian company town where coal mine doom meets fire-eyed-almost-deer and fatal sermons about salvation through suffering. After a run-in with a not-deer and a meet-and-greet with Mister T and his questionable Applejack theology, our heroes found themselves deep in the mines for mandatory community service, hammering rocks for redemption. Episode 2 picks up right where we left off: with moonshiner chaos, clumsy pickaxe injuries, Tommyknocker rituals, and a collapsing mine shaft that proves this town is as deadly belowground as it is above. In this episode of the RPGBOT Podcast, the gang digs deeper into Old Gods of Appalachia—both narratively and literally—as they're sent into the bowels of the Williams Holler coal mine to "earn their keep" under the watchful eye of foreman Josh CC. Join Jessie and Isaiah as they: Learn about Tommyknockers—ghostly Appalachian mine spirits who love pennies and hate eye contact. Perform citation-needed rituals involving canaries, fish bits, and whispered thanks. Fail basic pickaxe maneuvers (looking at you, Isaiah) and experience the dark gift of GM intrusions, brought to you by generous donors. Discover strange, ancient artifacts deep underground—hint: they might belong to the town's ominous apple orchard daughter. Encounter a creature that definitely isn't a dog made of coal and bad vibes. Try desperately to outrun physics, collapse, and tiny angry men with stone axes through lightless tunnels. All while raising money for MD Anderson Cancer Research, whose work helps real people—unlike some podcast characters we could name. Key Takeaways Horror is better underground: Claustrophobic tunnels, unstable lanterns, and monster-dust dogs? That's premium Appalachian fear. Cypher System shines in survival tension: Speed and might rolls build both narrative and actual sweat. Tommyknockers are the coal miner's cryptid: They warn you with knocks—if you leave them snacks and don't embarrass them. GM intrusions are extra spicy during charity games: The more you donate, the more you make the players quietly panic. Jessie can shoot, quip, and pull people out of holes: The perfect outlaw protagonist energy. This mine is getting worse by the minute: Strange artifacts, broken elevators, dead canaries? It's all very "maybe we leave now." Basket of weird fruit: The orchard, Mr. T, and a thing calling itself "the green" are part of a cosmic tug-of-war that's barely begun. Thank You to the Old Gods and Monte Cook A huge thank-you to Steve Shell, Cam Collins, and the DeepNerd Media team for creating the masterwork that is Old Gods of Appalachia. Their audio drama is the gold standard of Appalachian horror storytelling—and the Old Gods of Appalachia Roleplaying Game, built on Monte Cook Games' Cypher System, brings that dread to your table with terrifying finesse. Want to experience this world for yourself? Listen to Old Gods of Appalachia wherever you get your podcasts Buy the RPG at montecookgames.com/old-gods-of-appalachia-rpg Bring some "not a deer" terror into your next campaign Let the Old Gods whisper you home. Welcome to the RPGBOT Podcast. If you love Dungeons & Dragons, Pathfinder, and tabletop RPGs, this is the podcast for you. Support the show for free: Rate and review us on Apple Podcasts, Spotify, or any podcast app. It helps new listeners find the best RPG podcast for D&D and Pathfinder players. Level up your experience: Join us on Patreon to unlock ad-free access to RPGBOT.net and the RPGBOT Podcast, chat with us and the community on the RPGBOT Discord, and jump into live-streamed RPG podcast recordings. Support while you shop: Use our Amazon affiliate link at https://amzn.to/3NwElxQ and help us keep building tools and guides for the RPG community. Meet the Hosts Tyler Kamstra – Master of mechanics, seeing the Pathfinder action economy like Neo in the Matrix. Randall James – Lore buff and technologist, always ready to debate which Lord of the Rings edition reigns supreme. Ash Ely – Resident cynic, chaos agent, and AI's worst nightmare, bringing pure table-flipping RPG podcast energy. Join the RPGBOT team where fantasy roleplaying meets real strategy, sarcasm, and community chaos. How to Find Us: In-depth articles, guides, handbooks, reviews, news on Tabletop Role Playing at RPGBOT.net Tyler Kamstra BlueSky: @rpgbot.net TikTok: @RPGBOTDOTNET Ash Ely Professional Game Master on StartPlaying.Games BlueSky: @GravenAshes YouTube: @ashravenmedia Randall James BlueSky: @GrimoireRPG Amateurjack.com Read Melancon: A Grimoire Tale (affiliate link) Producer Dan @Lzr_illuminati

The RPGBOT crew descends into the haunted hollers of Appalachia—where faith, fire, and coal run deep, and the locals don't much care for outsiders asking questions. Between GM intrusions, cursed deer, and whiskey-soaked theology, our heroes quickly learn that in Old Gods of Appalachia, salvation's a dangerous business. Welcome to the mines, y'all—hope you brought your holy water and your lucky charm. Support the MD Anderson Cancer Center If you're looking to make a meaningful impact today, please consider donating to MD Anderson. Your gift supports cutting-edge cancer research, world-class patient care, and education & prevention efforts — all part of their mission to "Make Cancer History®." MD Anderson Cancer Center MD Anderson treats patients from around the globe, advances new therapies through clinical trials, and drives programs that prevent cancer before it starts.

In cancer care, ethical challenges rarely come with easy answers.When should treatment stop? How do teams manage moral distress? And what happens when AI begins to shape clinical decisions?In this episode, Dr. Nico Nortjé, Executive Director for the Center for Clinical Ethics in Cancer Care at MD Anderson Cancer Center, joins host Ginger to explore how oncology professionals navigate those moments when medical facts and human emotions collide.Dr. Nortjé shares what he's learned from leading ethics consultations, guiding care teams through end-of-life discussions, moral distress, and the new ethical questions raised by technology.You'll learn:How to recognize and address moral distress before it leads to burnoutHow ethics consults can turn uncertainty into team alignmentHow to approach treatment-limiting conversations with empathyWhat to consider when AI starts influencing care decisionsListen for a grounded, thoughtful look at what ethics really means in oncology today.

This new mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This first episode highlights the colon cancer operative standard. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center. Guest: George Chang, MD, MS, MHCM, FACS, FASCRS, FSSO is a Professor and the interim Department Chair in the Department of Colon and Rectal Surgery at MD Anderson Cancer Center.   Learning Objectives: The extent of colon mobilization and resection depends on tumor location, with high vascular ligation of the tumor-bearing segment to complete adequate regional lymphadenectomy. The technical steps of right colectomy are reviewed, including high ligation of the ileocolic pedicle at the level of the superior mesenteric vein, and the right branch of the middle colic artery if present. Tips and tricks are discussed to identify vascular structures and avoid central vascular injury. Links to Papers Referenced in this Episode Operative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colon https://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/ Kindle edition: https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSB Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomized, controlled, phase 3, superiority trial Lancet Oncol. 2021 Mar; 22(3):391-401. https://pubmed.ncbi.nlm.nih.gov/33587893/ Impact of Proximal Vascular Ligation on Survival of Patients with Colon Cancer. Ann Surg Oncol. 2018 Jan;25(1):38-45. https://pubmed.ncbi.nlm.nih.gov/27942902/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this inspiring episode of Black Men in Medicine, host Dr. Corey Gatewood sits down with Dr. Eric Flenaugh, a distinguished Critical Care Interventional Pulmonologist based in Atlanta, Georgia. Dr. Flenaugh serves as Associate Professor of Medicine, Vice Chair, and Chief of the Pulmonary Section at Morehouse School of Medicine and Grady Memorial Hospital, where he has dedicated his career to caring for Atlanta's diverse and underserved communities.A graduate of the University of Texas Health Science Center and MD Anderson Cancer Center, Dr. Flenaugh's journey reflects an unwavering commitment to excellence, mentorship, and advancing equity in healthcare.In this conversation, Dr. Flenaugh shares what drew him to the field of pulmonology and how his passion for critical care was tested—and ultimately strengthened—during the COVID-19 pandemic in one of the nation's least restricted states. He discusses leading with courage and compassion through unprecedented times, balancing the weight of loss with an enduring duty to serve.Dr. Flenaugh also highlights the importance of building and sustaining meaningful relationships, both within medicine and beyond, and how his experiences at Morehouse and Grady have deepened his sense of purpose. Together, he and Dr. Gatewood explore racial disparities in pulmonary health, from differences in lung cancer risk to inequities in access and diagnosis.Beyond the ICU, Dr. Flenaugh expresses his creativity as a filmmaker that allows him to find balance outside of medicine.Tune in for a candid, thought-provoking conversation that reminds us medicine is more than the treatment of disease, it's about breathing life into communities, relationships, and dreams. As we bring you nothing but the gems!

Dr. Beata Lerman is a distinguished scientist with over 22 years of biomedical development experience renowned for her work in immuno-oncology and cancer research at MD Anderson Cancer Center. Inspired by her personal battle with cutaneous T-cell lymphoma, she co-invented and patented two cancer immunotherapy treatments. After seeing the effect of the COVID-19 pandemic, especially on health compromised people, she founded Sinless Treats LLC and became a partner in Revogreen Inc. Beata makes her home in Houston, Texas.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Jesse Selber, MD, discuss the following articles from the September 2025 issue: “Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: The Laterothoracic Approach without Robotic Assistance” by Pozzo, Lhuaire, Mernier, et al. Read the article for FREE: https://bit.ly/NSM_IBR Special guest, Jesse Selber, MD, was most recently the Acting Chair, the Director of Clinical Research and Professor in the Department of Plastic Surgery at the University of Texas MD Anderson Cancer Center. Currently, he is a Physician Executive and the Surgery Service Line Chief of Beaumont, where he also serves as Professor of Plastic Surgery. In this role, Dr. Selber is responsible for all surgical activities within the Beaumont System, including 8 hospitals overseeing 2000 surgeons. Dr. Selber completed surgery residency at the University of Pennsylvania and fellowship in Microvascular Reconstructive Surgery at MD Anderson Cancer Center. Dr. Selber's clinical practice is exclusively complex cancer reconstruction. He is a surgical innovator, developing numerous techniques, and author of the only robotic plastic surgery textbook.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Sponsored By: → Cornbread Hemp | For an exclusive offer go to cornbreadhemp.com/drg and use promo code DRG for 30% OFF your first order! → JASPR | For an exclusive offer go to jaspr.co/DRG and get $200 OFF for a limited time. Sign up for our newsletter! https://drchristiangonzalez.com/newsletter/ Episode summary For empaths, introverts, and anyone who feels other people's moods deeply: this episode is for you. Dr. G sits down with Dr. Jason Yuan (ND)—a naturopathic doctor who blends energy healing with practical basics (sleep, minerals, breath, gut care). He explains pranic healing in plain English (think acupuncture without needles) and shares simple habits to use after hard talks, busy rooms, or long days. • Post-conversation reset (60–120s): pause, breathe a little slower through your nose, then say one release line (silently or aloud): “I release what isn't mine.” • Salt routine: in the shower, rub a handful of salt over shoulders/arms and rinse; or take a bath with 1–2 cups of salt to clear that heavy, lingering feeling. • Grounding: spend 5–10 minutes barefoot on grass/earth. No yard? Stand still indoors, feel your feet, and breathe slowly for a minute.• Why sensitive people “catch” the room's mood—and how to turn the volume down• How pranic (hands-off) energy work helps the body reset • Daily rhythm basics (sleep, minerals, steady meals) that make you more resilient About the guest: I'm with Dr. Jason Yuan, a naturopathic doctor who grounds energy practices in physiology—nervous system, breath, minerals, and gut. He cites mind–body research at MD Anderson Cancer Center where a healer's brain-state shifts were linked to changes in cells, and he turns those insights into simple, repeatable routines. Listen now to get the full walkthrough and context behind each step. Timestamps: 0:00 - Introduction 1:36 - Rapid Fire 4:43 - Dr. Yuan's Journey from Skeptic to Energy Healer 8:13 - 25 Years of Eczema: Personal Healing Story 11:57 - What Creates Energy Blocks and Congestion 16:44 - Research: MD Anderson Cancer Study Results 22:12 - Jesus & Collective Consciousness Healing 27:54 - The Three Bodies: Physical, Emotional & Mental 34:31 - Biofield vs Quantum Field Explained 39:30 - Soul as Driver: The Chariot Metaphor 45:07 - Practical Tools: Salt Baths & Energy Hygiene 50:32 - Energetic Cords: How People Drain Your Energy 55:18 - Virtual Sessions & Learning Pronic Healing